Título
Efficacy and safety of cemiplimab in the treatment of advanced cutaneous squamous cell carcinoma: A multicentre real-world retrospective study from Spain and systematic review of the published data.
Autor(es)
Palabras clave
Cemiplimab
Cutaneous squamous cell carcinoma
Multicentre real-world retrospective study
Fecha de publicación
2024-08
Editor
Wiley
Citación
Cañueto, J., Muñoz-Couselo, E., Cardona-Machado, C., Becerril-Andrés, S., Martín-Vallejo, J., Serra-Guillén, C., Soria, A., Serrano-Domingo, J.J., Ortiz-Velez, C., Lostes, J., García-Castaño, A., Puig, S., Fernández de Misa, R., Medina, J., Aguado, C., Ayala de Miguel, P., Navarro-Navarro, I., Masferrer, E., Delgado, M., Bellido-Hernández, L. and Sanmartin, O. (2024), Efficacy and safety of cemiplimab in the treatment of advanced cutaneous squamous cell carcinoma: A multicentre real-world retrospective study from Spain and systematic review of the published data. J Eur Acad Dermatol Venereol, 38: e666-e670. https://doi.org/10.1111/jdv.19821
Resumen
[EN]In this retrospective, observational, multicentre study,we searched for patients who were treated with systemic cemiplimab for advanced CSCC from 12 different Spanish centres (from 2019 to 2022). Patient demographics, primary tumour clinical and histological features, and other relevant medical history traits such as immunosuppression were collected.
URI
ISSN
0926-9959
DOI
Versión del editor
Collections
